• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.60% Nasdaq Down0.39%

    DURECT Corporation (DRRX)

    -NasdaqGM
    1.01 Down 0.01(0.98%) Feb 11, 4:00PM EST
    ProfileGet Profile for:
    DURECT Corporation
    10260 Bubb Road
    Cupertino, CA 95014
    United States - Map
    Phone: 408-777-1417
    Fax: 408-777-3577
    Website: http://www.durect.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:101

    Business Summary 

    DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. It provides ALZET product line comprising osmotic pumps and accessories that are used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers, which are used as raw materials for pharmaceutical and medical device under the LACTEL brand. It also focuses on developing products for various chronic and episodic, or acute medical conditions, including pain, central nervous system disorders, metabolic disorders, cardiovascular disease, ophthalmic disorders, and other diseases. The company develops REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a transdermal bupivacaine for the treatment of pain associated with post-herpetic neuralgia; and Relday, a risperidone product to treat the symptoms of schizophrenia and bipolar I disorder in adults and teenagers. It also develops ORADUR-ADHD, a drug candidate for the treatment of attention deficit hyperactivity disorder; ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials to treat chronic pain, and oxymorphone; and DUR-928, an endogenous small molecule for the treatment of acute organ injuries and metabolic/lipid disorders. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd., Impax Laboratories, Inc., Zogenix, Inc., Pain Therapeutics, Inc., and Hospira, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

    Key Statistics


    Company Websites 
    Home Page
    Investor Relations
    Search Yahoo! for:
    More on DURECT Corporation

    Corporate Governance 
    DURECT Corporation’s ISS Governance QuickScore as of Feb 1, 2016 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Felix Theeuwes D.Sc., Ph.D., 78
    Co-Founder, Chairman and Chief Scientific Officer
    294.00K0.00
    Dr. James E. Brown D.V.M., 59
    Co-Founder, Chief Exec. Officer, Pres and Director
    494.00K0.00
    Mr. Matthew J. Hogan M.B.A, 56
    Chief Financial Officer
    344.00K0.00
    Ms. Judy R. Joice , 59
    Sr. VP of Operations and Corp. Quality Assurance
    303.00K0.00
    Dr. Su Il Yum Ph.D., 77
    Exec. VP of Pharmaceutical Systems R&D
    371.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders